Role of IL-17 and Regulatory T Lymphocytes in a Systemic Autoimmune Disease

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2006 Nov 30

PMID 17130300

Citations 85

Authors

Jens Lohr

Birgit Knoechel

Jing Jing Wang

Alejandro V Villarino

Abul K Abbas

Affiliations

Soon will be listed here.

Abstract

To explore the interactions between regulatory T cells and pathogenic effector cytokines, we have developed a model of a T cell-mediated systemic autoimmune disorder resembling graft-versus-host disease. The cytokine responsible for tissue inflammation in this disorder is interleukin (IL)-17, whereas interferon (IFN)-gamma produced by Th1 cells has a protective effect in this setting. Because of the interest in potential therapeutic approaches utilizing transfer of regulatory T cells and inhibition of the IL-2 pathway, we have explored the roles of these in the systemic disease. We demonstrate that the production of IL-17 and tissue infiltration by IL-17-producing cells occur and are even enhanced in the absence of IL-2. Regulatory T cells favor IL-17 production but prevent the disease when administered early in the course by suppressing expansion of T cells. Thus, the pathogenic or protective effects of cytokines and the therapeutic capacity of regulatory T cells are crucially dependent on the timing and the nature of the disease.

Citing Articles

Silicone breast implant-associated pathologies and T cell-mediated responses.

Jagasia P, Taritsa I, Bagdady K, Shah S, Fracol M Inflamm Res. 2025; 74(1):33.

PMID: 39891670 DOI: 10.1007/s00011-025-02006-7.

Enhanced Effect of -Lactoglobulin Immunization in Mice with Mild Intestinal Deterioration Caused by Low-Dose Dextran Sulphate Sodium: A New Experimental Approach to Allergy Studies.

Zlotkowska D, Markiewicz L, Ogrodowczyk A, Wroblewska B, Wasilewska E Nutrients. 2024; 16(20).

PMID: 39458426 PMC: 11510979. DOI: 10.3390/nu16203430.

Baricitinib relieves DSS-induced ulcerative colitis in mice by suppressing the NF-κB and JAK2/STAT3 signalling pathways.

Wu Q, Liu Y, Liang J, Dai A, Du B, Xi X Inflammopharmacology. 2024; 32(1):849-861.

PMID: 38227095 DOI: 10.1007/s10787-023-01396-6.

Early human lung immune cell development and its role in epithelial cell fate.

Barnes J, Yoshida M, He P, Worlock K, Lindeboom R, Suo C Sci Immunol. 2023; 8(90):eadf9988.

PMID: 38100545 PMC: 7615868. DOI: 10.1126/sciimmunol.adf9988.

Systemic exposure to bacterial amyloid curli alters the gut mucosal immune response and the microbiome, exacerbating -induced arthritis.

Bessho S, Grando K, Kyrylchuk K, Miller A, Klein-Szanto A, Zhu W Gut Microbes. 2023; 15(1):2221813.

PMID: 37317012 PMC: 10269392. DOI: 10.1080/19490976.2023.2221813.

References

Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y . IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 2003; 100(10):5986-90. PMC: 156313. DOI: 10.1073/pnas.1035999100. View

Moseley T, Haudenschild D, Rose L, Reddi A . Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003; 14(2):155-74. DOI: 10.1016/s1359-6101(03)00002-9. View

Nakae S, Nambu A, Sudo K, Iwakura Y . Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003; 171(11):6173-7. DOI: 10.4049/jimmunol.171.11.6173. View

Reddy P . Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2004; 21(4):149-61. DOI: 10.1002/hon.716. View

Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y . Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004; 110(1):55-62. DOI: 10.1016/j.clim.2003.09.013. View

Witowski J, Ksiazek K, Jorres A . Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004; 61(5):567-579. PMC: 11138872. DOI: 10.1007/s00018-003-3228-z. View

Sakaguchi S . Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004; 22:531-62. DOI: 10.1146/annurev.immunol.21.120601.141122. View

Nelson B . IL-2, regulatory T cells, and tolerance. J Immunol. 2004; 172(7):3983-8. DOI: 10.4049/jimmunol.172.7.3983. View

You S, Slehoffer G, Barriot S, Bach J, Chatenoud L . Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14580-5. PMC: 521992. DOI: 10.1073/pnas.0404870101. View

10.

Kolls J, Linden A . Interleukin-17 family members and inflammation. Immunity. 2004; 21(4):467-76. DOI: 10.1016/j.immuni.2004.08.018. View

11.

Cousens L, Orange J, Biron C . Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. J Immunol. 1995; 155(12):5690-9. View

12.

Murphy W, Welniak L, Taub D, Wiltrout R, Taylor P, Vallera D . Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998; 102(9):1742-8. PMC: 509122. DOI: 10.1172/JCI3906. View

13.

Yang Y, Dey B, Sergio J, Pearson D, Sykes M . Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest. 1998; 102(12):2126-35. PMC: 509167. DOI: 10.1172/JCI4992. View

14.

Anderson B, McNiff J, Jain D, Blazar B, Shlomchik W, Shlomchik M . Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2004; 105(5):2227-34. DOI: 10.1182/blood-2004-08-3032. View

15.

Feldmann M, Steinman L . Design of effective immunotherapy for human autoimmunity. Nature. 2005; 435(7042):612-9. DOI: 10.1038/nature03727. View

16.

Sawitzki B, Kingsley C, Oliveira V, Karim M, Herber M, Wood K . IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med. 2005; 201(12):1925-35. PMC: 2212028. DOI: 10.1084/jem.20050419. View

17.

Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y . A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6(11):1133-41. PMC: 1618871. DOI: 10.1038/ni1261. View

18.

Harrington L, Hatton R, Mangan P, Turner H, Murphy T, Murphy K . Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6(11):1123-32. DOI: 10.1038/ni1254. View

19.

Knoechel B, Lohr J, Kahn E, Bluestone J, Abbas A . Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005; 202(10):1375-86. PMC: 2212975. DOI: 10.1084/jem.20050855. View

20.

Feldmann M, Brennan F, Foxwell B, Taylor P, Williams R, Maini R . Anti-TNF therapy: where have we got to in 2005?. J Autoimmun. 2005; 25 Suppl:26-8. DOI: 10.1016/j.jaut.2005.09.006. View